Arrowhead Pharmaceuticals Inc. (ARWR)

17.95
0.93 4.90
NASDAQ : Health Technology
Prev Close 18.88
Open 18.88
Day Low/High 17.97 / 18.91
52 Wk Low/High 3.01 / 22.39
Volume 868.40K
Avg Volume 2.24M
Exchange NASDAQ
Shares Outstanding 88.02M
Market Cap 1.64B
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Arrowhead Completes Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

Arrowhead Completes Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a...

Arrowhead Pharmaceuticals To Present At Upcoming September 2018 Conferences

Arrowhead Pharmaceuticals To Present At Upcoming September 2018 Conferences

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: Annual B.

First Week Of ARWR October 19th Options Trading

First Week Of ARWR October 19th Options Trading

Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new October 19th contracts and identified one put and one call contract of particular interest.

Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results

Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 third quarter ended June 30, 2018.

Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment From Amgen

Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment From Amgen

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study.

First Week Of March 2019 Options Trading For Arrowhead Pharmaceuticals (ARWR)

First Week Of March 2019 Options Trading For Arrowhead Pharmaceuticals (ARWR)

Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the March 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Pharmaceuticals To Webcast Fiscal 2018 Third Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2018 Third Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2018, at 4:30 p.

Arrowhead Pharmaceuticals Reaches Analyst Target Price

Arrowhead Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Arrowhead Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $15.83, changing hands for $16.45/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Arrowhead Presents New Clinical Data On ARO-AAT At Alpha-1 National Education Conference

Arrowhead Presents New Clinical Data On ARO-AAT At Alpha-1 National Education Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today will present preclinical and initial clinical data on ARO-AAT, the company's second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare...

Arrowhead Receives Positive EMA Opinion On Orphan Designation For ARO-AAT For Treatment Of Congenital Alpha-1 Antitrypsin Deficiency

Arrowhead Receives Positive EMA Opinion On Orphan Designation For ARO-AAT For Treatment Of Congenital Alpha-1 Antitrypsin Deficiency

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Arrowhead's application for orphan designation of its RNAi candidate,...

First Week Of August 17th Options Trading For Arrowhead Pharmaceuticals (ARWR)

First Week Of August 17th Options Trading For Arrowhead Pharmaceuticals (ARWR)

Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

Arrowhead Completes Enrollment In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

Arrowhead Completes Enrollment In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of a Phase 1 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a...

ARWR Crosses Above Average Analyst Target

ARWR Crosses Above Average Analyst Target

In recent trading, shares of Arrowhead Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $10.50, changing hands for $11.11/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 1, 2018, the Board of Directors approved "inducement" grants to 13 new employees under Rule 5635(c)(4) of the NASDAQ...

Arrowhead Pharmaceuticals Presents New Preclinical Data On ARO-ENaC For Treatment Of Cystic Fibrosis

Arrowhead Pharmaceuticals Presents New Preclinical Data On ARO-ENaC For Treatment Of Cystic Fibrosis

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, for the treatment of cystic fibrosis (CF), at the American Thoracic Society (ATS) 2018 International...

Arrowhead Doses First Hepatitis B Patients In Multiple Dose Portion Of Phase 1/2 Study Of ARO-HBV

Arrowhead Doses First Hepatitis B Patients In Multiple Dose Portion Of Phase 1/2 Study Of ARO-HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first 3 hepatitis B virus (HBV) patients in the multiple-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company's third generation subcutaneously...

Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic Pipeline

Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic Pipeline

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of new preclinical data on its expanding pipeline of RNA interference (RNAi) therapeutics for cardiometabolic diseases, including ARO-ANG3, which targets angiopoietin-like...

Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results

Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 second quarter ended March 31, 2018.

Arrowhead Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Arrowhead Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $7.75, changing hands for $7.77/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Arrowhead Pharmaceuticals To Present Preclinical Data On Emerging Pipeline Of RNAi Therapeutics

Arrowhead Pharmaceuticals To Present Preclinical Data On Emerging Pipeline Of RNAi Therapeutics

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present preclinical data on ARO-ANG3 and ARO-APOC3, its two candidates targeting cardiometabolic diseases, and ARO-ENaC, formerly referred to as ARO-Lung1, its first candidate to...

First Week Of December 21st Options Trading For Arrowhead Pharmaceuticals (ARWR)

Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the December 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Pharmaceuticals To Webcast Fiscal 2018 Second Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2018 Second Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 8, 2018, at 4:30 p.

Arrowhead Pharmaceuticals Announces Multiple Presentations At The International Liver Congress™

Arrowhead Pharmaceuticals Announces Multiple Presentations At The International Liver Congress™

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical and pre-clinical data on the company's investigational medicines for the treatment of chronic hepatitis B infection (ARC-520 and...

Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV For Treatment Of Chronic Hepatitis B

Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV For Treatment Of Chronic Hepatitis B

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2 clinical study of ARO-HBV, which is being developed as a potentially curative therapy for patients with...

Arrowhead Pharmaceuticals Reaches Analyst Target Price

Arrowhead Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Arrowhead Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $7.30, changing hands for $7.32/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 16, 2018, the Board of Directors approved "inducement" grants to six new employees...

TheStreet Quant Rating: D- (Sell)